Blog Posts - Malignant Mesothelioma



Treatments to prolong life for mesothelioma patients closer

Researchers have uncovered a strange way that asbestos-related tumours grow, which could pave the way towards better treatments. The scientists at Adelaide’s Flinders University have found that malignant mesothelioma tumours are able to transfo...
by AsbestosHUB on Nov 15, 2016

New Paradigms in the Treatment of Mesothelioma and NSCLC: An Overview by Fred Hirsch

Dr. Haffizulla: Welcome to PracticeUpdate. I’m Dr. Farzanna Haffizulla. Joining me today is Dr. Fred Hirsch, CEO of the International Association for the Study of Lung Cancer, and Professor of Medicine at the University of Colorado in Denver. Dr.
by AsbestosHUB on Nov 11, 2016

Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma

Malignant pleural mesothelioma shows marked cytoarchitectural diversity. The aim of the study was to evaluate how morphological phenotype impacted upon overall survival. 191 cases of malignant pleural mesothelioma with available follow-up were identi...
by AsbestosHUB on Nov 10, 2016

Residual fibre lung burden among patients with pleural mesothelioma who have been occupationally exposed to asbestos

Objectives  To evaluate the lungs asbestos fibres concentration in participants with malignant pleural mesothelioma (MPM) who have been occupationally exposed. Methods  The lung samples were obtained from pleuropneumonectomies or autopsies of 271 m...
by AsbestosHUB on Nov 8, 2016

Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy

Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. Recently, we emphasi...
by AsbestosHUB on Nov 2, 2016

Arginine Deprivation for Malignant Pleural Mesothelioma

Arginine deprivation is a novel anticancer strategy in argininosuccinate synthetase 1 (ASS1)–negative tumors. In a multicenter, phase II trial, immunohistochemistry identified 68 patients with ASS1 deficiency among 201 patients with malignant pleur...
by AsbestosHUB on Oct 26, 2016

Scientists discover new option for treating malignant pleural mesothelioma

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. For the first time in the world, they were able to show in a preclinical study, both...
by AsbestosHUB on Oct 24, 2016

Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review

Abstract Background Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5–10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or...
by AsbestosHUB on Oct 19, 2016

For Malignant Pleural Mesothelioma The Identification Of Molecular Profiles Is Helpful In Selecting Targeted Therapies

A relatively new medical journal article reports on a development which may improve survival time for those men and women who, unfortunately, have developed malignant pleural mesothelioma (MPM). From the Abstract for a 2014 Clinical Cancer Research a...
by AsbestosHUB on May 20, 2014

Progression Of Malignant Pleural Mesothelioma Might Be Slowed Down By Systemic Delivery Of Stem Cells

New medical research out of the United Kingdom (UK) suggests using stem cell therapy to decrease tumor burden as a new possible treatment of malignant pleural mesothelioma. From a March 19, 2014 news report, “Systemic stem cell therapy reduces...
by AsbestosHUB on May 13, 2014

The Radical Surgery Procedure Extrapleural Pneumonectomy (EPP) Is Controversial, At Best, As A Treatment Of Malignant Pleural Mesothelioma

Extrapleural pneumonectomy (EPP) as a surgical treatment of malignant pleural mesothelioma became popular in the 1990s due, in part, to a number of papers authored by the renowned Dr. David Sugarbaker. Now, however, that particular surgery option for...
by AsbestosHUB on Apr 29, 2014

Well-Known Mesothelioma Medical Doctor David Sugarbaker Moving From Brigham And Women’s Hospital To Lung Disease Center At Baylor College Of Medicine

A leader in the care of pleural mesothelioma, Dr. David Sugarbaker, will direct the mesothelioma clinical and research program at the Lung Institute, a new comprehensive lung disease center at Baylor College of Medicine in Texas. From a March 24, 201...
by AsbestosHUB on Apr 21, 2014

A Few New Immunotherapy Mesothelioma Treatment Options Were Discussed At The European Lung Cancer Conference 2014

Some investigational immunotherapy drugs that act on the programmed cell death pathway in lung cancer patients are now being considered as a new treatment means for patients with mesothelioma. Several presentations at the recent European Lung Cancer...
by AsbestosHUB on Mar 28, 2014

New Therapy Approach Has A Double Effect On Malignant Mesothelioma Cells Says Medical Researchers In Vermont

There seems to be some hopeful news coming out of the Department of Pathology at the University of Vermont College of Medicine in Burlington, Vermont. In January 2014 an article written by some researchers there was published online by the Cancer Pre...
by AsbestosHUB on Feb 27, 2014

If Someone You Know Has Or Had Asbestos Mesothelioma, Did They Happen To Smoke Kent Cigarettes In The 1950s?

In October 2013 Mother Jones magazine published an article with this attention getting headline, “Remember When Big Tobacco Sold Asbestos as the ‘Greatest Health Protection’?”. From that news story by Myron Levin: It’s h...
by AsbestosHUB on Feb 10, 2014

New Medical Study About Mesothelioma Treatment Shows Benefit Of Radiation Therapy Prior To Surgical Procedure

In January 2014 there was some apparent good news regarding how one might medically treat individuals who have developed mesothelioma. In short, a recent article published by the Journal of Thoracic Oncology suggests that the treatment of mesotheliom...
by AsbestosHUB on Jan 22, 2014

Federal Court Bankruptcy Judge George Hodges Gives Asbestos Defendant Garlock What They Wanted And More, Which Is Unfortunate For Mesothelioma Victims

Last summer we were monitoring a bankruptcy estimation trial for the former asbestos company Garlock Sealing Technologies in Charlotte, North Carolina and being presided over by federal bankruptcy judge George Hodges. This Garlock Chapter 11 case is...
by AsbestosHUB on Jan 13, 2014

National Institute For Occupational Safety And Health (NIOSH) Study About Deaths From Mesosthelioma And Asbestosis Published In January 2014 Medical Journal

From the Abstract for this recently published 2014 article about the loss of life attributable to asbestosis and malignant mesothelioma, “Diseases attributable to asbestos exposure: Years of potential life lost, United States, 1999-2010″,...
by AsbestosHUB on Jan 7, 2014

Surgical Procedure Is Good Treatment Option For Patients With Certain Type Of Malignant Pleural Mesothelioma (MPM) According To New Medical Study

The following comes from a December 2013 news article, “Chest wall resection effective for recurrent mesothelioma”, about some recent medical research findings published in The Journal of Thoracic and Cardiovascular Surgery: Salvage ches...
by AsbestosHUB on Dec 18, 2013

SEPREHVIR(R) (HSV1716), An Oncolytic Virus For Possible Treatment Of Malignant Pleural Mesothelioma: Phase I/IIa Clinical Study Underway As Of August 2013

Virttu Biologics Limited, a UK biotechnology company, issued this press release in late August 2013, “Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR(R) Study in Mesothelioma.&#...
by AsbestosHUB on Sep 17, 2013


Trending Topics

Close